BRISTOL-MYERS SQUIBB’s BETAPACE ANTI-ARRHYTHMIC BETA BLOCKER RECOMMENDED CONDITIONALLY FOR APPROVAL; ADMISSIBILITY OF INTERIM TRIAL DATA DEBATED